75 results about "Neisseria sp" patented technology

A hybrid protein contains a protein that binds to a receptor of mastocytes and basophils and is endocyted by them. The protein can be IgE; IgE fragment; IgE Fc fragment; antibody against IgE receptor of mastocytes and basophils; fragment of the antibody against the IgE receptor of mastocytes and basophils; antibody against mastocyte specific potassium channel; and mast cell degranulating peptide. The hybrid protein also contains a protease cleaving proteins of the secretion process of the mastocytes and basophils so as to inhibit the secretion process without killing the mastocytes and basophils. The protease can be light chain Clostridium botulinum toxin; proteolytically active fragment of the light chain of a Clostridium botulinum toxin containing an amino acid sequence His-Xaa-Xaa-Xaa-His-Xaa-Xaa-His wherein Xaa is an amino acid; light chain of the tetanus toxin; proteolytically active fragment of the light chain of the tetanus toxin containing His-Asp-Leu-lIe-His-Val-Leu-His; IgA protease of Neisseria gonorrhoeae; and proteolytic domain of the IgA protease of Neisseria gonorrhoeae.

Provided are recombinant DNA molecules that do not occur in nature encoding an O-acetyltransferase, vectors that direct expression of an O-acetyltransferase, recombinant host cells which express an O-acetyltransferase, methods for recombinant production of an O-acetyltransferase, methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using a recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.

The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and / or diagnostics.

This invention relates to modified meningococcal Y polysaccharides (GYMP), conjugates comprising the modified polysaccharides and a carrier, vaccines for the immunisation of warm-blooded animals, including humans, against Group Y Neisseria meningitidis, and to methods for producing these modified polysaccharides, conjugates and vaccines.

The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.

An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.

The invention provides a method for detecting mutation of drug-resistant sites of 19 neisseria gonorrhoeae. The method utilizes a multiplex PCR-mass spectrometry method to detect the mutation of the drug-resistant sites of the 19 neisseria gonorrhoeae. The detection method comprises the following steps: 1) designing primers for different drug-resistant sites; 2) carrying out multiplex PCR amplification reaction; 3) treating shrimp alkaline phosphatase; 4) carrying out single base extension reaction; 5) desalting and purifying resin; and 6) carrying out mass spectrometric detection.

The invention belongs to the technical field of molecular biology detection, and relates to a detection method for drug resistance sites, in particular to a method and a kit for multiple detection ofthe drug resistance sites of neisseria gonorrhoeae. A provided specific primer for the multiple detection of the drug resistance sites of the neisseria gonorrhoeae selects drug-resistance-related genes of two drug combinations (ceftriaxone and azithromycin) as target genes for detection, and includes penA, ponA, porB, mtrR, and 23S rRNA. Based on high resolution melting curve analysis technique, the DNA demulsification process is monitored in real time through high resolution melting of PCR products, the mutation condition of the genes is analyzed according to the characteristic change of a melting curve, and thus a basis is provided for determining the drug-resistant condition of the neisseria gonorrhoeae.

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and / or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and / or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and / or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and / or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and / or nucleic acids.

The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics. Relying on this personalized diagnostic tool, physicians can better inform about antibiotic susceptibility and thereby open up medical intervention avenues for treating Neisseria gonorrhoeae with antibiotics. There is provided a therapeutic application of the antibiotic resistance profile that has advantages of: (i) providing a more effective regime for gonorrhea treatment; and (ii) halting the evolutionary pressures towards antibiotic resistance in the Neisseria gonorrhoeae therapy.

Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.

Meningococcal antigens are cleaved by human lactoferrin. The invention is based on the identification of the cleavage products of this reaction, and provides a method for cleaving a neisserial polypeptide, comprising the step of mixing the polypeptide with a lactoferrin enzyme. The invention also provides polypeptides obtainable by this process (i.e. the cleavage products of the lactoferrin digestion) which might be useful in the preparation of anti-meningococcal vaccines. Proteins of particular interest are meningococcal proteins 287 and App.

An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from Neisseria meningitidis serogroups A, C, W135 and Y, thereby producing a combined vaccine. The aqueous formulation can include various immunogens but does not include a Hib conjugate.

The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and / or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and / or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and / or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and / or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and / or nucleic acids.

The invention belongs to the technical field of molecular biological detection, relates to a detection method for pathogenic microorganisms, and in particular relates to a visualization method for rapidly detecting neisseria gonorrhoeae by utilizing a recombinase polymerase isothermal amplification technology. According to the method, by combining the recombinase polymerase isothermal amplification technology and fluorescent dye developing, rapid amplification of neisseria gonorrhoeae nucleic acids can be realized under the condition that a PCR (Polymerase Chain Reaction) instrument and any other heat cycle equipment are not used. The results are identified by observing the color change of the reaction system with naked eyes. According to related reagents provided by the invention, the neisseria gonorrhoeae in samples can be rapidly detected by virtue of simple treatment of to-be-detected samples, and the detection method has the advantages of being simple in operation, high in specificity, capable of determining the results with naked eyes, and the like, and is applicable to clinical diagnosis and individual early screening.

The present disclosure relates to, inter alia, a method of treating a patient in need of treatment with a C5 inhibitor or a method for inhibiting formation of terminal complement in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to a patient who is or will be in compliance with vaccination with a Neisseria meningococcal Type B specific vaccine.

Methods and compositions for immunizing a human subject against Neisseria gonorrhoeae.

Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 μg / ml.

Disclosed herein are primers and probes related to the detection of Neisseria gonorrhoeae via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of N. gonorrhoeae nucleic acids present in test samples. Specifically the present disclosure describes primers and probes that bind to the small subunit rRNA (cytosine (967)-C(5))-methyltransferase or rsmB gene of N. gonorrhoeae for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

The invention relates to a real-time PCR (polymerase chain reaction) method for quintuply detecting target nucleic acid in a nucleic acid extracting solution in a single PCR reaction vessel, which is used for detecting Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis and Mycoplasma genitalium in a sample.

The present invention discloses a mutant Neisseria having extensive membrane blebbing, both an indicium and a cause of virulence in the gonococcus and meningococcus. Methods are disclosed for making and characterizing the mutant, bmrRS. Methods are disclosed for isolating bmrRS membranes for use as a vaccine. Methods are also disclosed for the use of the mutant for determining the virulence of clinical samples of N. gonorrhoeae and N. meningitidis. Methods are also disclosed for the screening of antibiotics targeted to virulent Neisseria.

This invention provides compositions and methods for detecting Neisseria gonorrhoeae in a sample. This invention also provides related reaction mixtures, kits, systems, and computers.

An 85kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.